Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.

Clin Diagn Lab Immunol. 1994 Jul;1(4):482-5. Unique Identifier : AIDSLINE MED/96050859
Mercure L; Lalonde R; Phaneuf D; Brenner B; Wainberg MA; McGill University AIDS Centre, Montreal, Quebec, Canada.

Abstract: Although several studies have shown that 3'-azido-3'-deoxythymidine (AZT) is not toxic for CD4+ lymphocytes, its effect on CD8+ cells has never been studied in a systematic way. We purified CD8+ cells from the peripheral blood mononuclear cells of both human immunodeficiency virus (HIV)-seronegative and HIV-infected individuals by means of magnetic beads that had been coated with monoclonal antibodies. We report that AZT, but not two other nucleosides tested, inhibited the interleukin-2-dependent proliferation of CD8+ lymphocytes in a dose-dependent manner. No such effect was observed with regard to CD4(+)-enriched populations. The AZT-mediated antiproliferative effect did not appear to be related to either the CD4+ count or to prior treatment with this drug in the case of HIV-seropositive subjects.
Keywords: Antiviral Agents/*IMMUNOLOGY/PHARMACOLOGY Cell Division/IMMUNOLOGY CD8-Positive T-Lymphocytes/CYTOLOGY/DRUG EFFECTS/*IMMUNOLOGY Didanosine/IMMUNOLOGY/PHARMACOLOGY Human Interleukin-2/*ANTAGONISTS & INHIB/IMMUNOLOGY Lymphocyte Transformation/DRUG EFFECTS Support, Non-U.S. Gov't Zalcitabine/ANALOGS & DERIVATIVES/IMMUNOLOGY/PHARMACOLOGY Zidovudine/IMMUNOLOGY/*PHARMACOLOGY JOURNAL ARTICLEKWDantiviralagents/KWDimmunology/pharmacologycelldivision/immunologycd8-positivet-lymphocytes/cytology/drugeffects/KWDimmunologydidanosine/immunology/pharmacologyhumaninterleukin-2/KWDantagonists&inhib/immunologylymphocytetransformation/drugeffectssupport,non-uKWDsKWDgov'tzalcitabine/analogs&derivatives/immunology/pharmacologyzidovudine/immunology/KWDpharmacologyjournalarticle
960530
M9651019

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .